Using AI and a blood test to screen pacemaker patients for heart failure
Tests AI-assisted hand-held heart scans and a finger-prick blood test for heart failure.
Key facts
- Who runs it
- University of Leeds
- Where
- Leeds, United KingdomSee the site
- Trial code
- Registry title
- OPTimising a Screening Program to Detect Pacemaker-associated Heart Failure Using Artificial Intelligence
- Status
- Enrolling by invitation
- People taking part
- 150 people, planned
- Started
- 7 Oct 2025
- Planned end
- Sept 2026
- Type of study
- Observational
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a pacemaker who have not been diagnosed with heart failure. It tests new ways to screen for heart failure.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Pacemaker with right ventricular pacing burden of 20% or more. No known heart failure.
- Earlier treatment
- Must already have a pacemaker. Must not have a conduction system pacemaker, a cardiac resynchronisation therapy pacemaker/defibrillator, an implantable cardioverter defibrillator or a leadless pacemaker.
- Biomarker or test result
- Must never have had a left ventricular ejection fraction below 50%.
Main reasons for not taking part
- Known heart failure
- Any past left ventricular ejection fraction below 50%
- Conduction system pacemaker
- Cardiac resynchronisation therapy pacemaker/defibrillator
- Implantable cardioverter defibrillator or leadless pacemaker
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult patients aged ≥18 years
- Patients with existing pacemakers who have a right ventricular pacing burden ≥20%
- Ability to provide informed consent
Who cannot take part
- Patients known to have heart failure
- Patients with cardiac resynchronisation therapy pacemakers/defibrillators
- Patients with any previous measurement of left ventricular ejection fraction <50%
- Patients who are unwilling or unable to provide informed consent
- Patients with conduction system pacemakers
- Patients with implantable cardioverter defibrillators
- Patients with leadless pacemakers
Where in United Kingdom
- Cardiovascular Research Facility, Leeds General InfirmaryLeeds, United KingdomEnrolling by invitation
About the trial
What the trial wants to find out
Pacemakers are an effective treatment for slow heart rates which improve symptoms and save lives. However, for some people pacemakers can cause heart failure (HF) because of the unnatural way in which they stimulate heart beats. In several studies conducted in West Yorkshire we showed that ~1/3 of patients with pacemakers have undiagnosed HF. We also showed that where HF is discovered, treating it with safe and inexpensive medications reduces the chances of being admitted to hospital or dying. However, detecting HF requires an echocardiogram (a heart ultrasound scan) which takes ~45 minutes, requires a skilled technician, and costs £120; or, to put it another way ~£540,000 to assess the ~4,500 patients cared for at our hospital. A new approach is needed. We think that using new technologies can improve our ability to screen for HF in people with pacemakers. We will test two approaches. First, we will assess whether a hand-held echocardiogram can measure heart function using artificial intelligence (AI) as accurately as a standard echocardiogram done by a skilled technician. Second, we will assess whether a finger-prick blood test can detect the presence of abnormal function as accurately as a standard echocardiogram.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- OPTimising a Screening Program to Detect Pacemaker-associated Heart Failure Using Artificial Intelligence
- Plain-language title
- Using AI and a blood test to screen pacemaker patients for heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 28 January 2026